Cargando…
Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD)
Metabolic (dysfunction) associated fatty liver disease (MAFLD) is recognized as the most prevalent chronic liver disease globally. However, its pathogenesis remains incompletely understood. Recent advancements in the gut-liver axis offer novel insights into the development of MAFLD. Polysaccharides,...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10489936/ https://www.ncbi.nlm.nih.gov/pubmed/37686754 http://dx.doi.org/10.3390/nu15173722 |
_version_ | 1785103724001099776 |
---|---|
author | Guo, Qin Li, Yun Dai, Xin Wang, Bangmao Zhang, Jie Cao, Hailong |
author_facet | Guo, Qin Li, Yun Dai, Xin Wang, Bangmao Zhang, Jie Cao, Hailong |
author_sort | Guo, Qin |
collection | PubMed |
description | Metabolic (dysfunction) associated fatty liver disease (MAFLD) is recognized as the most prevalent chronic liver disease globally. However, its pathogenesis remains incompletely understood. Recent advancements in the gut-liver axis offer novel insights into the development of MAFLD. Polysaccharides, primarily derived from fungal and algal sources, abundantly exist in the human diet and exert beneficial effects on glycometabolism, lipid metabolism, inflammation, immune modulation, oxidative stress, and the release of MAFLD. Numerous studies have demonstrated that these bioactivities of polysaccharides are associated with their prebiotic properties, including the ability to modulate the gut microbiome profile, maintain gut barrier integrity, regulate metabolites produced by gut microbiota such as lipopolysaccharide (LPS), short-chain fatty acids (SCFAs), and bile acids (BAs), and contribute to intestinal homeostasis. This narrative review aims to present a comprehensive summary of the current understanding of the protective effects of polysaccharides on MAFLD through their interactions with the gut microbiota and its metabolites. Specifically, we highlight the potential molecular mechanisms underlying the prebiotic effects of polysaccharides, which may give new avenues for the prevention and treatment of MAFLD. |
format | Online Article Text |
id | pubmed-10489936 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104899362023-09-09 Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD) Guo, Qin Li, Yun Dai, Xin Wang, Bangmao Zhang, Jie Cao, Hailong Nutrients Review Metabolic (dysfunction) associated fatty liver disease (MAFLD) is recognized as the most prevalent chronic liver disease globally. However, its pathogenesis remains incompletely understood. Recent advancements in the gut-liver axis offer novel insights into the development of MAFLD. Polysaccharides, primarily derived from fungal and algal sources, abundantly exist in the human diet and exert beneficial effects on glycometabolism, lipid metabolism, inflammation, immune modulation, oxidative stress, and the release of MAFLD. Numerous studies have demonstrated that these bioactivities of polysaccharides are associated with their prebiotic properties, including the ability to modulate the gut microbiome profile, maintain gut barrier integrity, regulate metabolites produced by gut microbiota such as lipopolysaccharide (LPS), short-chain fatty acids (SCFAs), and bile acids (BAs), and contribute to intestinal homeostasis. This narrative review aims to present a comprehensive summary of the current understanding of the protective effects of polysaccharides on MAFLD through their interactions with the gut microbiota and its metabolites. Specifically, we highlight the potential molecular mechanisms underlying the prebiotic effects of polysaccharides, which may give new avenues for the prevention and treatment of MAFLD. MDPI 2023-08-25 /pmc/articles/PMC10489936/ /pubmed/37686754 http://dx.doi.org/10.3390/nu15173722 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Guo, Qin Li, Yun Dai, Xin Wang, Bangmao Zhang, Jie Cao, Hailong Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD) |
title | Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD) |
title_full | Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD) |
title_fullStr | Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD) |
title_full_unstemmed | Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD) |
title_short | Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD) |
title_sort | polysaccharides: the potential prebiotics for metabolic associated fatty liver disease (mafld) |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10489936/ https://www.ncbi.nlm.nih.gov/pubmed/37686754 http://dx.doi.org/10.3390/nu15173722 |
work_keys_str_mv | AT guoqin polysaccharidesthepotentialprebioticsformetabolicassociatedfattyliverdiseasemafld AT liyun polysaccharidesthepotentialprebioticsformetabolicassociatedfattyliverdiseasemafld AT daixin polysaccharidesthepotentialprebioticsformetabolicassociatedfattyliverdiseasemafld AT wangbangmao polysaccharidesthepotentialprebioticsformetabolicassociatedfattyliverdiseasemafld AT zhangjie polysaccharidesthepotentialprebioticsformetabolicassociatedfattyliverdiseasemafld AT caohailong polysaccharidesthepotentialprebioticsformetabolicassociatedfattyliverdiseasemafld |